Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP & General Mgr, Industrial | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,673 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 2,552 · Balance 21,673 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 12,376 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,376 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,129 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,129 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $608.29 | $486,632.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,403 F2 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on February 23, 2022 at prices ranging from $608.01 to $608.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 156 | $607.94 | $94,838.64 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,203 F1 · price: Represents volume-weighted average price of sales of 156 shares of Company stock on February 23, 2022 at prices ranging from $607.92 to $607.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 23, 2022 at each separate price. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · derivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 33,219 | $610.56 | $20,282,192.64 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,359 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 40,000 | $399.66 | $15,986,400.00 |
DisclosureSEC source: 0001708138-22-000018 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 697 | $664.34 | $463,044.98 |
DisclosureSEC source: 0001883850-21-000029 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,578 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,548 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001708138-21-000095 · edgardoc.xml · derivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,548 Underlying: Common Stock · 18,548 shares Expires 2031-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 4,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000095 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,275 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $660.51 | $330,255.00 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,931 F8 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on November 16, 2021 at prices ranging from $660.33 to $660.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,403 | $659.42 | $1,584,586.26 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,431 F7 · price: Represents volume-weighted average price of sales of 2,403 shares of Company stock on November 16, 2021 at prices ranging from $659.01 to $659.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 697 | $658.50 | $458,974.50 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,834 F6 · price: Represents volume-weighted average price of sales of 697 shares of Company stock on November 16, 2021 at prices ranging from $658.03 to $658.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $657.18 | $131,436.00 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,531 F5 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 16, 2021 at prices ranging from $657.09 to $657.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 350 | $655.03 | $229,260.50 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,731 F4 · price: Represents volume-weighted average price of sales of 350 shares of Company stock on November 16, 2021 at prices ranging from $655.01 to $655.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,260 | $654.33 | $824,455.80 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,081 F3 · price: Represents volume-weighted average price of sales of 1,260 shares of Company stock on November 16, 2021 at prices ranging from $654.03 to $654.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 840 | $653.41 | $548,864.40 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,341 F2 · price: Represents volume-weighted average price of sales of 840 shares of Company stock on November 16, 2021 at prices ranging from $653.03 to $653.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 528 | $652.20 | $344,361.60 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,181 F1 · price: Represents volume-weighted average price of sales of 528 shares of Company stock on November 16, 2021 at prices ranging from $652.01 to $652.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · derivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 18,222 | $641.50 | $11,689,413.00 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,709 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $270.43 | $6,760,750.00 |
DisclosureSEC source: 0001708138-21-000085 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $616.27 | $184,881.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 13 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,931 F10 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 10, 2021 at prices ranging from $616.01 to $616.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 280 | $615.22 | $172,261.60 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 12 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,231 F9 · price: Represents volume-weighted average price of sales of 280 shares of Company stock on August 10, 2021 at prices ranging from $615.00 to $615.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,120 | $614.33 | $688,049.60 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 11 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,511 F8 · price: Represents volume-weighted average price of sales of 1,120 shares of Company stock on August 10, 2021 at prices ranging from $614.08 to $614.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,600 | $613.34 | $981,344.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 10 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,631 F7 · price: Represents volume-weighted average price of sales of 1,600 shares of Company stock on August 10, 2021 at prices ranging from $613.07 to $613.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $612.45 | $551,205.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 9 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,231 F6 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on August 10, 2021 at prices ranging from $612.03 to $612.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $611.57 | $244,628.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 8 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,131 F5 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on August 10, 2021 at prices ranging from $611.22 to $611.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $610.81 | $61,081.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 7 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,531 Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $609.25 | $121,850.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,631 F4 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 10, 2021 at prices ranging from $609.21 to $609.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 697 | $608.50 | $424,124.50 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,831 F3 · price: Represents volume-weighted average price of sales of 697 shares of Company stock on August 10, 2021 at prices ranging from $608.17 to $608.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 762 | $607.21 | $462,694.02 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,528 F2 · price: Represents volume-weighted average price of sales of 762 shares of Company stock on August 10, 2021 at prices ranging from $607.00 to $607.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 244 | $606.50 | $147,986.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,290 F1 · price: Represents volume-weighted average price of sales of 244 shares of Company stock on August 10, 2021 at prices ranging from $606.32 to $606.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · derivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 18,397 | $617.68 | $11,363,458.96 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,534 Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 21:54 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $270.43 | $6,760,750.00 |
DisclosureSEC source: 0001708138-21-000049 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr, Industrial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,950 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000115 · edgardoc.xml · derivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,950 Underlying: Common Stock · 19,950 shares Expires 2030-12-09 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000115 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,931 F2 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 9, 2025. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000115 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,931 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,288 | $614.24 | $791,141.12 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 6 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,001 F6 · price: Represents volume-weighted average price of sales of 1,288 shares of Company stock on August 25, 2020 at prices ranging from $614.00 to $614.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,560 | $613.62 | $957,247.20 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 5 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,289 F5 · price: Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 25, 2020 at prices ranging from $613.08 to $613.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,044 | $612.49 | $2,476,909.56 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,849 F4 · price: Represents volume-weighted average price of sales of 4,044 shares of Company stock on August 25, 2020 at prices ranging from $612.00 to $612.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,980 | $611.40 | $1,210,572.00 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,893 F3 · price: Represents volume-weighted average price of sales of 1,980 shares of Company stock on August 25, 2020 at prices ranging from $611.00 to $611.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,981 | $610.41 | $4,871,682.21 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,873 F2 · price: Represents volume-weighted average price of sales of 7,981 shares of Company stock on August 25, 2020 at prices ranging from $610.01 to $610.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,256 | $609.71 | $6,253,185.76 |
DisclosureSEC source: 0001708138-20-000101 · edgardoc.xml · nonDerivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,854 F1 · price: Represents volume-weighted average price of sales of 10,256 shares of Company stock on August 25, 2020 at prices ranging from $609.18 to $609.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001104659-20-098009 · a4.xml · derivative · entry 4 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 47,891 | $614.09 | $29,409,384.19 |
DisclosureSEC source: 0001104659-20-098009 · a4.xml · nonDerivative · entry 3 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,110 F1 · balance_after: Reflects transfers to the reporting person's former spouse that were exempt from reporting. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 75,000 | $179.13 | $13,434,750.00 |
DisclosureSEC source: 0001104659-20-098009 · a4.xml · nonDerivative · entry 2 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects transfers to the reporting person's former spouse that were exempt from reporting. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $569.42 | $398,594.00 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 18 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,251 F13 · price: Represents volume-weighted average price of sales of 700 shares of Company stock on May 7, 2020 at prices ranging from $569.02 to $569.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,040 | $568.57 | $1,728,452.80 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 17 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,951 F12 · price: Represents volume-weighted average price of sales of 3,040 shares of Company stock on May 7, 2020 at prices ranging from $568.10 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,753 | $567.35 | $2,129,264.55 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 16 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,991 F11 · price: Represents volume-weighted average price of sales of 3,753 shares of Company stock on May 7, 2020 at prices ranging from $567.00 to $567.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,297 | $566.47 | $4,133,531.59 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 15 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,744 F10 · price: Represents volume-weighted average price of sales of 7,297 shares of Company stock on May 7, 2020 at prices ranging from $566.00 to $566.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,984 | $565.49 | $3,383,892.16 |
DisclosureSEC source: 0001708138-20-000052 · edgardoc.xml · nonDerivative · entry 14 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,041 F9 · price: Represents volume-weighted average price of sales of 5,984 shares of Company stock on May 7, 2020 at prices ranging from $565.03 to $565.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.